A multicenter phase II study of continuous dosing of sunitinib (Sutent, SU11248) in non-GIST [non-gastrointestinal stromal tumuor] sarcomas
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- 20 Oct 2009 Planned number of patients changed from 82 to 102 as reported by ClinicalTrials.gov.
- 21 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov..
- 10 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.